Pfizer is set to partner with University of California (UC), San Diego Health Sciences via its Centers for Therapeutic Innovation (CTI) network to accelerate and transform drug discovery and development.

Pfizer expects to invest up to $50m including milestone payments to UC San Diego Health Sciences for successful projects over a five-year period.

The partnership allows scientists from both parties to work together in a dedicated lab space at Pfizer’s La Jolla research and development campus.

Pfizer BioTherapeutics Research and Development senior vice-president and head Jose Carlos Gutierrez-Ramos said the goal is to bridge the gap between scientific discovery and the delivery of promising candidates to the pipeline.

Pfizer will also provide funding for the pre-clinical and clinical development of sponsored programs, offer CTI partners equitable intellectual property rights and grant milestone payments and royalties related to the advancement of drug candidates.